| Literature DB >> 29464546 |
Bogna Grygiel-Górniak1, Elżbieta Kaczmarek2, Maria Mosor3, Juliusz Przysławski4, Jerzy Nowak3.
Abstract
As ageing and increased body fat are the signs of insulin resistance, we have studied whether the presence of Pro12Ala and C1431T of peroxisome proliferator-activated receptor gamma 2 gene and Trp64Arg of beta 3-adrenergic receptor gene may predispose to the hyperglycaemia development in postmenopausal women, who have never undergone hypoglycaemic treatment. The distributions of selected allele and genotype frequencies were determined by the PCR-RFLP method in normo- and hyperglycaemic, who have never been diagnosed and treated for diabetes mellitus were measured. The amount of body fat and lean body mass (LBM) were assessed by the bioimpedance method and nutritional habits by 7-day dietary recall. There were no differences between the distribution of genotypes and the allele frequencies of the Pro12Ala, C1431T and Trp64Arg polymorphisms in normo- and hyperglycaemic women. Hyperglycaemic women were characterized by visceral obesity, hypertension, higher serum insulin and triglycerides, higher intake of fat and lower consumption of complex carbohydrates and B vitamins. Normoglycaemic women with Pro12Pro polymorphism acquired higher energy from dietary fat (p < 0.0276) and lower energy from carbohydrates (p < 0.0480) than normoglycaemic Ala12 carriers. Subjects with Pro12Pro polymorphism and LBM > 58% of total body mass or with Trp64Trp and normal triglycerides have higher chance of normoglycaemia. Genotyping for Pro12Ala and Trp64Arg polymorphism in postmenopausal women may have the clinical benefit of predicting hyperglycaemia, thereby contributing to the prevention of diabetes mellitus development in the future. However, not only the genetic background but also the dietary habits (intake of fat, carbohydrates and B vitamins) determine the risk of hyperglycaemia.Entities:
Keywords: Genetic background; Newly diagnosed hyperglycaemia; Nutritional habits; Postmenopausal obesity
Mesh:
Substances:
Year: 2018 PMID: 29464546 PMCID: PMC5895664 DOI: 10.1007/s13353-018-0434-9
Source DB: PubMed Journal: J Appl Genet ISSN: 1234-1983 Impact factor: 3.240
Genotype and allele frequencies of the Pro12Ala and C1431/X PPAR gamma 2 and Trp64Arg of beta-adrenergic receptor gene polymorphisms according to normoglycaemic (glucose < 100 mg/dl) and hyperglycaemic state (glucose > 100 mg/dl). Data are n (%) for genotypes and n (frequency) for alleles
| Body fat distribution | Normoglycaemic | Hyperglycaemic | OR | 95% CI | |||
|---|---|---|---|---|---|---|---|
| Observed | Expected (%) | Observed | Expected (%) | ||||
| Genotype (Pro12Ala) | |||||||
| CC (Pro12Pro) | 130 (67) | 133 (68.6) | 55 (71.4) | 53 (68.8) | 0.81 | 0.46–1.45 | ns |
| CG (Pro12Ala) | 57 (29.4) | 54 (27.8) | 19 (24.7) | 22 (27.3) | 1.23 | 0.69–2.19 | ns |
| GG (Ala12Ala) | 7 (3.6) | 7 (3.6) | 3 (3.9) | 3 (3.9) | – | – | |
| Allele | |||||||
| C | 317 (81.70) | – | 129 (83.77) | – | |||
| G | 71 (18.30) | – | 25 (16.23) | – | |||
| Genotype (C1431T) | |||||||
| CC (C1431C) | 143 (73.7) | 157 (80.9) | 55 (71.4) | 63 (81.8) | 1.21 | 0.62–2.02 | ns |
| CT (C1431T) | 47 (24.2) | 34 (17.5) | 19 (24.7) | 13 (16.9) | 0.89 | 0.49–1.61 | ns |
| TT (T1431 T) | 4 (2.1) | 3 (1.5) | 3 (3.39) | 1 (1.3) | – | ||
| Allele | |||||||
| C | 333 (85.82) | – | 129 (83.77) | – | |||
| T | 55 (14.18) | – | 25 (16.23) | – | |||
| Genotype (Trp64Arg) | |||||||
| TT (Trp64Trp) | 159 (81.9) | 142 (73.2) | 61 | 56 (72.7) | 1.19 | 0.62–2.31 | ns |
| TC (Trp64Arg) | 31 (16) | 47 (24.2) | 16 | 19 (24.7) | 0.84 | 0.43–1.63 | ns |
| CC (Arg64Arg) | 4 (2.1) | 5 (2.6) | – | 2 (2.6) | |||
| Allele | |||||||
| T | 349 (89.95) | – | 138 (89.61) | – | |||
| C | 39 (10.05) | – | 16 (10.39) | – | |||
Anthropometric, biochemical and nutritional characteristics of normo- and hyperglycaemic women
| Analysed parameters | Normoglycaemic | Hyperglycaemic | |
|---|---|---|---|
| Age (years) | 58.73 ± 5.58 | 60.77 ± 4.89 | 0.0055 |
| Body height (cm) | 161.13 ± 6.02 | 160.47 ± 5.25 | 0.4048 |
| Body mass (kg) | 74.12 ± 16.52 | 82.02 ± 14.44 | 0.0003 |
| WC (cm) | 87.91 ± 14.66 | 96.61 ± 11.20 | 0.00001 |
| WHR | 0.83 ± 0.08 | 0.86 ± 0.06 | 0.0002 |
| BMI (kg/m2) | 28.49 ± 6.35 | 31.76 ± 5.63 | 0.0001 |
| Body fat (%) | 42.40 ± 6.63 | 46.16 ± 6.22 | 0.00001 |
| LBM (%) | 57.74 ± 6.51 | 53.77 ± 6.32 | 0.00001 |
| Systolic pressure (mmHg) | 137.06 ± 21.45 | 151.73 ± 21.86 | 0.00001 |
| Diastolic pressure (mmHg) | 86.08 ± 12.73 | 92.77 ± 14.50 | 0.0002 |
| FSH (mIU/ml) | 74.10 ± 20.77 | 59.89± | 0.0001 |
| Insulin (U/ml) | 8.57 ± 7.32 | 12.49 ± 7.26 | 0.0001 |
| Glucose (mg/dl) | 90.28 ± 6.53 | 112.37 ± 13.77 | 0.00001 |
| HOMA–IR [(mU/ml) × (mmol/l))] | 1.93 ± 1.64 | 3.53± 2.33 | 0.00001 |
| TC (mg/dl) | 228.01 ± 39.96 | 238.10 ± 42.77 | 0.0673 |
| HDL (mg/dl) | 65.38 ± 14.94 | 60.50 ± 13.55 | 0.0135 |
| TG (mg/dl) | 105.56 ± 41.93 | 147.56 ± 67.58 | 0.0000 |
| LDL (mg/dl) | 141.55 ± 35.99 | 148.02 ± 38.36 | 0.1914 |
| Energy (kcal) | 2046.39 ± 552.40 | 2057.39 ± 575.11 | 0.8839 |
| Protein (% energy) | 16.27 ± 3.37 | 16.39 ± 3.09 | 0.8002 |
| Fat (% energy) | 33.58 ± 5.46 | 35.19 ± 4.70 | 0.0238 |
| Carbohydrates (% energy) | 51.03 ± 6.92 | 49.19 ± 6.05 | 0.0421 |
| Dietary fibre (g) | 22.75 ± 7.46 | 21.50 ± 7.01 | 0.2056 |
| Vitamin B12 (μg) | 2.97 ± 2.52 | 2.31 ± 1.65 | 0.0352 |
| Biotyna (μg) | 25.37 ± 11.54 | 22.36 ± 10.53 | 0.0479 |
| Pantothenic acid (mg) | 3.19 ± 1.17 | 2.81 ± 1.10 | 0.0164 |
| Free folacin (μg) | 115.82 ± 43.69 | 104.27 ± 39.39 | 0.0447 |
| Total folacin (μg) | 234.13 ± 86.69 | 211.79 ± 73.46 | 0.0472 |
Anthropometrical, biochemical and nutritional characteristics of postmenopausal women with polymorphisms of PPAR gamma 2 and ADRβ3 genes
| Analysed parameters | ||||||
|---|---|---|---|---|---|---|
| Polymorphism Pro12Ala | Polymorphism Ala12/X | Polymorphism Pro12Pro | ||||
| Normoglycaemic, | Hyperglycaemic, | Normoglycaemic, | Hyperglycaemic, | |||
| Body fat (%) | 42.98 ± 6.97 | 45.73 ± 6.11 | ns | 42.11 ± 6.46 | 46.34 ± 6.31 | 0.0001 |
| LBM (%) | 57.01 ± 6.96 | 54.32 ± 6.14 | ns | 58.10 ± 6.28 | 53.55 ± 6.44 | 0.00001 |
| Systolic pressure (mmHg) | 135.80 ± 20.72 | 153.27 ± 25.71 | 0.0055 | 137.68 ± 21.84 | 151.11 ± 20.35 | 0.0002 |
| Diastolic pressure (mmHg) | 85.45 ± 12.29 | 94.59 ± 16.83 | 0.0377 | 86.38 ± 12.98 | 92.04 ± 13.56 | 0.0034 |
| Insulin (mU/ml) | 9.72 ± 11.37 | 12.05 ± 6.36 | 0.0043 | 8.00 ± 4.01 | 12.66 ± 7.63 | 0.00001 |
| HDL (mg/dl) | 64.96 ± 16.93 | 62.58 ± 10.88 | ns | 65.58 ± 13.92 | 59.67 ± 14.49 | 0.0084 |
| TG (mg/dl) | 109.20 ± 40.34 | 159.75 ± 89.96 | 0.0128 | 103.76 ± 42.73 | 142.68 ± 56.53 | 0.00001 |
| Fat (% energy) | 32.22 ± 4.45* | 36.73 ± 5.11 | 0.0005 | 34.25 ± 5.80* | 34.57 ± 4.43 | ns |
| Carbohydrates (% energy) | 52.72 ± 5.78** | 47.25 ± 6.34 | 0.0002 | 50.19 ± 7.29* | 49.97 ± 5.80 | ns |
| VitaminB12 (μg) | 3.04 ± 2.71 | 2.07 ± 1.15 | 0.0495 | 2.93 ± 2.43 | 2.41 ± 1.82 | ns |
| Vitamin B7 (biotin) (μg) | 25.93 ± 11.94 | 21.57 ± 9.30 | ns | 25.10 ± 11.37 | 22.67 ± 11.05 | ns |
| Pantothenic acid (mg) | 3.17 ± 1.08 | 2.70 ± 1.05 | ns | 3.20 ± 1.22 | 2.86 ± 1.13 | 0.0481 |
| Polymorphism C1431T | Polymorphism T1431/X | Polymorphism C1431C | ||||
| Normoglycaemic, | Hyperglycaemic, | Normoglycaemic, | Hyperglycaemic, | |||
| Body fat (%) | 43.56 ± 8.14 | 44.69 ± 7.23 | ns | 42.14 ± 6.24 | 46.55 ± 5.93 | 0.00001 |
| LBM (%) | 56.87 ± 7.78 | 55.31 ± 7.23 | ns | 57.93 ± 6.22 | 53.36 ± 6.06 | 0.00001 |
| Systolic pressure (mmHg) | 133.63 ± 21.67 | 156.06 ± 23.23 | ns | 137.82 ± 21.39 | 150.59 ± 21.54 | 0.00001 |
| Diastolic pressure (mmHg) | 84.74 ± 12.21 | 93.75 ± 14.22 | ns | 86.37 ± 12.86 | 92.51 ± 14.68 | 0.00001 |
| Insulin (mU/ml) | 8.02 ± 4.31 | 14.50 ± 7.29 | 0.0182 | 8.69 ± 7.83 | 11.96 ± 7.21 | 0.00001 |
| HDL (mg/dl) | 65.40 ± 14.96 | 64.24 ± 11.73 | ns | 65.37 ± 14.98 | 59.52 ± 13.91 | 0.0366 |
| TG (mg/dl) | 120.35 ± 56.10 | 130.16 ± 54.75 | 0.0250 | 102.30 ± 37.57 | 152.12 ± 70.24 | 0.00001 |
| Fat (% energy) | 33.81 ± 3.59 | 35.10 ± 4.87 | ns | 33.25 ± 5.54 | 35.55 ± 4.91 | 0.0148 |
| Carbohydrates (% energy) | 50.68 ± 3.71 | 49.54 ± 5.79 | ns | 51.36 ± 7.12 | 48.80 ± 6.49 | 0.0101 |
| Vitamin B12 (μg) | 3.52 ± 3.07 | 2.17 ± 0.96 | 0.0220 | 2.85 ± 2.38 | 2.35 ± 1.80 | ns |
| Vitamin B7 (biotin) (μg) | 27.67 ± 12.48 | 21.47 ± 8.63 | 0.0493 | 24.87 ± 11.30 | 22.59 ± 11.02 | ns |
| Pantothenic acid (mg) | 3.40 ± 1.3 | 3.00 ± 1.15 | 0.0319 | 3.14 ± 1.14 | 2.77 ± 1.09 | ns |
| Polymorphism Trp64Arg | Arg64/X | Trp64/Trp | ||||
| Normoglycaemic, | Hyperglycaemic, | Normoglycaemic, | Hyperglycaemic, | |||
| Body fat (%) | 43.56 ± 8.14 | 44.69 ± 7.23 | ns | 42.14 ± 6.24 | 46.55 ± 5.93 | 0.00001 |
| LBM (%) | 56.87 ± 7.78 | 55.31 ± 7.23 | ns | 57.93 ± 6.22 | 53.36 ± 6.06 | 0.00001 |
| Systolic pressure (mmHg) | 133.63 ± 21.67 | 156.06 ± 23.23 | 0.0033 | 137.82 ± 21.39 | 150.59 ± 21.54 | 0.0003 |
| Diastolic pressure (mmHg) | 84.74 ± 12.21 | 93.75 ± 14.22 | 0.0217 | 86.37 ± 12.86 | 92.51 ± 14.68 | 0.0031 |
| Insulin (mU/ml) | 8.02 ± 4.31 | 14.50 ± 7.29 | 0.0014 | 8.69 ± 7.83 | 11.96 ± 7.21 | 0.00001 |
| HDL (mg/dl) | 65.40 ± 14.96 | 64.24 ± 11.73 | ns | 65.37 ± 14.98 | 59.52 ± 13.91 | 0.0101 |
| TG (mg/dl) | 120.35 ± 56.10 | 130.16 ± 54.75 | ns | 102.30 ± 37.57 | 152.12 ± 70.24 | 0.0000 |
| Fat (% energy) | 33.81 ± 3.59 | 35.10 ± 4.87 | ns | 33.25 ± 5.54 | 35.55 ± 4.91 | 0.0008 |
| Carbohydrates (% energy) | 50.68 ± 3.71 | 49.54 ± 5.79 | ns | 51.36 ± 7.12 | 48.80 ± 6.49 | 0.0035 |
| Vitamin B12 (μg) | 3.52 ± 3.07 | 2.17 ± 0.96 | ns | 2.85 ± 2.38 | 2.35 ± 1.80 | ns |
| Vitamin B7 (biotin) (μg) | 27.67 ± 12.48 | 21.47 ± 8.63 | ns | 24.87 ± 11.30 | 22.59 ± 11.02 | ns |
| Pantothenic acid (mg) | 3.40 ± 1.31 | 3.00 ± 1.15 | ns | 3.14 ± 1.14 | 2.77 ± 1.09 | 0.0175 |
LBM lean body mass
*p < 0.0276; **p < 0.0480 p values between analysed polymorphisms
Analysis of the risk of hyperglycaemia in analysed groups
| Analysed polymorphism | Analysed groups |
| % |
| % |
|---|---|---|---|---|---|
| Pro12Pro | LBM > 58% | LBM ≤ 58 | |||
| Normoglycaemic | 184 | 74.2 | 17 | 51.5 | |
| Hyperglycaemic | 64 | 25.8 | 16 | 48.5 | |
| Sum | 248 | 100 | 33 | 100 | |
| OR = 3.44 | (1.69–7.01) | OR = 0.29 | (0.14–0.59) | ||
| Trp64Trp | TG ≤ 150 mg/dl | TG > 150 mg/dl | |||
| Normoglycaemic | 140 | 80.5 | 19 | 41.3 | |
| Hyperglycaemic | 40 | 19.5 | 21 | 58.7 | |
| Sum | 180 | 100 | 46 | 100 | |
| OR = 3.87 | (1.90–7.89) | OR = 0.26 | (0.13–0.53) | ||